Preclinical data supports rationale for SLS009 in pancreatic cancer but does not change near-term valuation. The next catalyst is clinical data from ongoing SLS009 trials in AML or other indications — monitor for Phase 2 readouts rather than preclinical updates.
Price Chart
Executive Summary
SELLAS Life Sciences presented preclinical data at AACR showing its CDK9 inhibitor SLS009 induced substantially greater apoptosis (17.9% vs 2.8%) than the RAS inhibitor daraxonrasib in a daraxonrasib-resistant MYC-amplified pancreatic cancer organoid model, and the combination further increased apoptosis to 36.5%. The data also showed synergistic activity with BET inhibition, supporting further evaluation of SLS009-based combinations in pancreatic cancer. This is early preclinical data with no regulatory or clinical milestone — the impact is limited for a late-stage biotech with a separate lead asset (GPS).
Key Facts
- SLS009 monotherapy induced 17.9% apoptosis vs 2.8% for daraxonrasib in a daraxonrasib-resistant PDAC organoid model
- SLS009 + daraxonrasib combination induced 36.5% apoptosis and 30.6% necrosis
- SLS009 + BET inhibitor ZEN3694 showed synergistic activity with sustained MYC suppression
- Data presented at AACR Pancreatic Cancer Conference, September 25-28, 2026 in San Diego
- Preclinical data only — no clinical trial results or regulatory milestones announced
Financial Impact
No financial data provided; preclinical data with no immediate revenue or cost impact
Risk Factors
- Preclinical results may not translate to clinical efficacy in humans
- SLS009 is early-stage for pancreatic cancer — no clinical trials in this indication have been initiated
- Company's lead asset is GPS (WT1-targeting), not SLS009; SLS009 is a secondary pipeline candidate
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3369263 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | Press Release | $11.61 | awaiting T+60 | — | $12.17 (+4.82%) |
Jun 2, 2026 21w ago | 8-K | $8.33 $13.73 | ▲ +64.83% | ▲ +63.71% | $12.17 (+46.10%) |
May 12, 2026 24w ago | 8-K | $6.53 $12.01 | ▲ +83.92% | ▲ +79.48% | $12.17 (+86.37%) |
Apr 23, 2026 26w ago | DEFA14A | $4.46 $12.90 | ▲ +189.24% | ▲ +184.16% | $12.17 (+172.87%) |
Mar 19, 2026 31w ago | Press Release | $4.76 $7.83 | ▲ +64.50% | ▲ +50.08% | $12.17 (+155.67%) |
Mar 17, 2026 32w ago | Press Release | $4.95 $7.75 | ▲ +56.57% | ▲ +45.04% | $12.17 (+145.86%) |
Mar 12, 2026 32w ago | Press Release | $5.03 $8.23 | ▲ +63.62% | ▲ +52.92% | $12.17 (+141.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers